middle.news
Imugene’s Azer-cel Posts 81% Response in CAR T-Naïve Blood Cancer Patients
9:27am on Friday 22nd of May, 2026 AEST
•
Healthcare
Read Story
Imugene’s Azer-cel Posts 81% Response in CAR T-Naïve Blood Cancer Patients
9:27am on Friday 22nd of May, 2026 AEST
Key Points
81% overall response rate in CAR T-naïve cohort
Complete and partial responses across multiple lymphoma subtypes
Robust CAR T-cell expansion with manageable safety profile
New BTKi combination cohort opened for resistant patients
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE